These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32940343)

  • 1. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.
    Leutz A; Pinter A; Thaçi D; Augustin M; Schuster C; Fotiou K; Hundemer HP; Saure D; Mrowietz U; Reich K
    Br J Dermatol; 2021 Mar; 184(3):548-550. PubMed ID: 32940343
    [No Abstract]   [Full Text] [Related]  

  • 2. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.
    Reich K; Augustin M; Thaçi D; Pinter A; Leutz A; Henneges C; Schneider E; Schacht A; Dossenbach M; Mrowietz U
    Br J Dermatol; 2020 Apr; 182(4):869-879. PubMed ID: 31376153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Syed YY
    Am J Clin Dermatol; 2017 Feb; 18(1):147-158. PubMed ID: 28138946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
    Dickel H; Bruckner T; Altmeyer P
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
    Thaçi D; Pinter A; Sebastian M; Termeer C; Sticherling M; Gerdes S; Wegner S; Krampe S; Bartz H; Rausch C; Mensch A; Eyerich K
    Br J Dermatol; 2020 Aug; 183(2):265-275. PubMed ID: 31705526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
    JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
    Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
    Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.
    Romiti R; Valenzuela F; Chouela EN; Xu W; Pangallo B; Moriarty SR; Gürbüz S; Riedl E
    Br J Dermatol; 2019 Jul; 181(1):202-203. PubMed ID: 30609008
    [No Abstract]   [Full Text] [Related]  

  • 13. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
    Brunner PM; Conrad C; Vender R; Grond S; Schuster C; Patel H; Xu W; Carrascosa Carrillo JM
    Br J Dermatol; 2021 Oct; 185(4):865-867. PubMed ID: 34076896
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 15. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
    Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
    Ryan C; Menter A; Guenther L; Blauvelt A; Bissonnette R; Meeuwis K; Sullivan J; Cather JC; Yosipovitch G; Gottlieb AB; Merola JF; Callis Duffin K; Fretzin S; Osuntokun OO; Burge R; Naegeli AN; Yang FE; Lin CY; Todd K; Potts Bleakman A;
    Br J Dermatol; 2018 Oct; 179(4):844-852. PubMed ID: 29747232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
    Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
    Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
    Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
    J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.